STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Rhea-AI Summary

Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. President and CEO John C. Jacobs and Chief Medical Officer Dr. Jeffrey Dayno will host investor meetings during the event. The presentation will be accessible via a webcast on Harmony's investor page. The company focuses on developing therapies for rare neurological disorders with unmet medical needs.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+0.40% News Effect

On the day this news was published, HRMY gained 0.40%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John C. Jacobs and Chief Medical Officer, Dr. Jeffrey Dayno will present a company update and host investor meetings at the Oppenheimer Rare and Orphan Disease Summit on Friday, May 21, 2021.

A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/

About Harmony Biosciences 
Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Investor Contact: 

Lisa Caperelli 
484-539-9736 
lcaperelli@harmonybiosciences.com 

Harmony Biosciences Media Contact: 

Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit-301293012.html

SOURCE Harmony Biosciences

FAQ

What is Harmony Biosciences presenting at the Oppenheimer Rare and Orphan Disease Summit?

Harmony Biosciences will present a company update on May 21, 2021.

Who is presenting for Harmony Biosciences at the summit?

John C. Jacobs, President and CEO, and Dr. Jeffrey Dayno, Chief Medical Officer, will present.

Where can I access the webcast of Harmony Biosciences' presentation?

The webcast will be available on Harmony's investor page at their website.

When is the Oppenheimer Rare and Orphan Disease Summit?

The summit is scheduled for May 21, 2021.

What is the focus of Harmony Biosciences?

Harmony Biosciences focuses on developing therapies for rare neurological disorders with unmet medical needs.
Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

HRMY Rankings

HRMY Latest News

HRMY Latest SEC Filings

HRMY Stock Data

2.29B
48.84M
11.04%
95.18%
7.53%
Biotechnology
Pharmaceutical Preparations
Link
United States
PLYMOUTH MEETING